Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SOM-230

Known as: SOM 230, SOM230 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
CONTEXT There is currently no medical therapy for Cushing's disease that targets the pituitary adenoma. Availability of such a… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Review
2008
Review
2008
  • H. Schmid
  • Molecular and Cellular Endocrinology
  • 2008
  • Corpus ID: 8975340
Pasireotide (SOM230) is a multi-receptor ligand somatostatin analogue with high binding affinity for somatostatin receptor… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
CONTEXT There is no tumor-directed medical therapy available for Cushing's disease. OBJECTIVE The objective was to determine… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
In a series of human corticotroph adenomas, we recently found predominant mRNA expression of somatostatin (SS) receptor subtype 5… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
OBJECTIVE Currently, there is no effective medical treatment for patients with pituitary-dependent Cushing's disease. A novel… Expand
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Functional gastroenteropancreatic tumors express all 5 somatostatin receptor subtypes (sst) in different quantities. Octreotide… Expand
  • table 1
  • figure 1
  • table 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
To determine the inhibitory profile of the novel somatostatin (SRIF) analog SOM230 with broad SRIF receptor binding, we compared… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Treatment with the somatostatin receptor (sst) subtype 2 predominant analogs octreotide and lanreotide induces clinical and… Expand
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
Highly Cited
2002
Highly Cited
2002
OBJECTIVE The aim of the present study was to identify a small, metabolically stable somatotropin release inhibiting factor (SRIF… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?